Thursday, August 21, 2014 7:10:58 PM
I did also notice that by June 11th, 9 had received at least 4 injections (week 0,1,2,8), and 20 had at least 3 (week 0,1,2). By Aug 11th therefore, we could conclude that 9 had received at least 5 injections (week 0,1,2,8,16), and 20 had at least 4 (week 0,1,2,8).
If they announced the Ph I leg was fully enrolled Jul 16, then these last enrolled patients should complete the regimen by Feb 2015 (then two months after that they would assess again. They do this every two months for 24 months provided they are surviving). I would imagine, considering the trial concludes June 2015, that the Ph II leg may begin to be enrolled some 8 weeks after the last enrollees to Ph I have received three doses, plus assessment. Maybe by October. And I suspect the lowest dose will be selected. No idea which indication. BUT, they may not even begin enrolling the Ph II leg until later than this.
In the PR it also states:
Which may still be on. I mean, what's the worst that could happen? AF gets another statement saying, "MD anderson still does not approve of sharing early data of an ongoing trial." Who cares?
Anyway, we just might receive another update on patient progress soon, in a couple months, or at a more "acceptable" interim moment, such as when the majority of the 36 patients have received all 6 vaccinations, plus some time for assessment of the last dose's effect (8 weeks thereafter). 20/36 would reach all 6 doses plus 8 weeks assessment by early winter.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM